Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Respiratory syncytial virus.in: Mandell G.L. Bennett J.E. Dolin R. Principles and practices of infectious disease. vol. 6. Elsevier Churchill Livingstone, Philadelphia2004: 2008-2026
- Immunity to and frequency of reinfection with respiratory syncytial virus.J Infect Dis. 1991; 163: 693-698
- Mortality associated with influenza and respiratory syncytial virus in the United States.JAMA. 2003; 289: 179-186
- Respiratory syncytial virus infection in elderly and high-risk adults.N Engl J Med. 2005; 352: 1749-1759
- Viral and host factors in human respiratory syncytial virus pathogenesis.J Virol. 2008; 82: 2040-2055
- Monoclonal antibodies protect against respiratory syncytial virus.Lancet. 1983; 2: 976
- Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies.Infect Immun. 1984; 43: 756-758
- Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies.J Gen Virol. 1986; 67: 505-513
- Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. IMpact-RSV Study Group.Pediatrics. 1998; 102: 531-537
- Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.J Virol. 2002; 76: 5654-5666
- Immune responses and disease enhancement during respiratory syncytial virus infection.Clin Microbiol Rev. 2005; 18: 541-555
- Respiratory syncytial virus and T cells: interplay between the virus and the host adaptive immune system.Proc Am Thorac Soc. 2005; 2: 141-146
- Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.J Clin Invest. 1991; 88: 1026-1033
- CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells.Clin Exp Immunol. 1992; 88: 527-536
- T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice.J Clin Invest. 1997; 99: 2183-2191
- Pathogenesis of respiratory syncytial virus infection in the murine model.Proc Am Thorac Soc. 2005; 2: 110-115
- Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3–6 months after immunization.Vaccine. 1990; 8: 497-502
- Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.Int Immunol. 1992; 4: 493-500
- Vaccines against human respiratory syncytial virus.in: Cane P.A. Respiratory syncytial virus. Elsevier, Amsterdam2007: 233-277
- Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.Am J Epidemiol. 1969; 89: 435-448
- An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.Am J Epidemiol. 1969; 89: 405-421
- Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.Am J Epidemiol. 1969; 89: 449-463
- Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.Am J Epidemiol. 1969; 89: 422-434
- Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.J Clin Microbiol. 1988; 26: 1595-1597
- Respiratory syncytial virus (RSV)-induced airway hyper-responsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.J Infect Dis. 2000; 182: 671-677
- Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus.J Virol. 1986; 57: 721-728
- Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial.J Infect Dis. 1982; 145: 311-319
- New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.Proc Am Thorac Soc. 2005; 2: 166-173
- Low-temperature grown RS virus in adult volunteers.JAMA. 1968; 204: 142-146
- Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.J Infect Dis. 2000; 182: 1331-1342
- Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers.Vaccine. 1993; 11: 473-478
- Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.J Virol. 1999; 73: 871-877
- A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.Virology. 1998; 247: 232-239
- The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive, and attenuation mutations.Vaccine. 1999; 17: 1416-1424
- Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.J Virol. 1998; 72: 4467-4471
- Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees.J Virol. 2000; 74: 9317-9321
- Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.J Infect Dis. 2005; 191: 1093-1104
- The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.J Infect Dis. 2006; 193: 573-581
- Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection.J Infect Dis. 1987; 155: 1198-1204
- Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge.J Infect Dis. 1991; 163: 477-482
- Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.Vaccine. 1989; 7: 533-540
- Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus.Vaccine. 2003; 21: 4348-4358
- Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease.Vaccine. 2001; 19: 2048-2054
- Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.Nat Med. 2009; 15: 34-41
- Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.J Infect Dis. 1993; 168: 1024-1029
- Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18–36 months old.J Infect Dis. 1993; 167: 191-195
- Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.Pediatr Infect Dis J. 1994; 13: 792-798
- Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.Pediatr Infect Dis J. 1996; 15: 23-31
- Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.J Infect Dis. 1998; 177: 467-469
- Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multicenter trial in children with cystic fibrosis.Vaccine. 2003; 21: 2448-2460
- Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.Vaccine. 1996; 14: 1214-1218
- Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women.Vaccine. 2003; 21: 3465-3467
- Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.Virology. 1997; 230: 155-166
- Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.Vaccine. 2004; 22: 915-922
- Current research on respiratory viral infections: fourth international symposium.Antiviral Res. 2002; 55: 227-278
- Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high-risk elderly individuals.J Infect Dis. 2008; 198: 1317-1326
- Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection.Arch Virol. 1991; 117: 59-71
- Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice.Viral Immunol. 2007; 20: 261-275
- Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model.Vaccine. 2007; 25: 6211-6223
- Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G-glycoprotein.Virology. 1991; 185: 749-757
- Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines.Vaccine. 1999; 17: 832-836
- The coming of age of virus-like particle vaccines.Biol Chem. 2008; 389: 521-536
- Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).Drugs. 2006; 66 ([discussion: 1272–3]): 1263-1271
- Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.J Virol. 2006; 80: 3975-3984
- Subnucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.PLoS One. 2008; 3: e1766
- Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.J Virol. 1991; 65: 1634-1637
- Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.Vaccine. 1999; 18: 392-397
- Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.Vaccine. 1990; 8: 164-168
- A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.Vaccine. 1993; 11: 1395-1404
- Vaccination of infant macaques with a recombinant modified vaccinia virus ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.Vaccine. 2004; 22: 923-926
- Recombinant sendai virus as a novel vaccine candidate for respiratory syncytial virus.Viral Immunol. 2005; 18: 255-266
- Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3′ proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.J Virol. 2003; 77: 10819-10828
- Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.J Virol. 2001; 75: 4594-4603
- Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.J Virol. 2002; 76: 1089-1099
- Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys.J Virol. 2004; 78: 11198-11207
- Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides.Vaccine. 2000; 18: 2743-2752
- Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.J Virol. 2007; 81: 13710-13722
- Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.Vaccine. 2007; 25: 7132-7144
- Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.J Virol. 2006; 80: 1130-1139
- Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic.Virology. 2001; 281: 216-230
- Protection against respiratory syncytial virus infection by DNA immunization.J Exp Med. 1998; 188: 681-688
- Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.Virology. 2000; 269: 54-65
- Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection.Hum Gene Ther. 2002; 13: 1415-1425
- Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein.Vaccine. 2000; 19: 1038-1046
Article info
Footnotes
This work was supported by Grant Number AI076781 from the National Institutes of Health. Dr. Murata is also a coauthor of a provisional patent application on the use of human papillomavirus L1 capsid protein and its derivatives as respiratory syncytial virus vaccine candidates.
Identification
Copyright
© 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
